Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -4.27
- Piotroski Score 4.00
- Grade Buy
- Symbol (BBIO)
- Company BridgeBio Pharma, Inc.
- Price $25.45
- Changes Percentage (2.04%)
- Change $0.51
- Day Low $24.79
- Day High $26.15
- Year High $44.32
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/30/2024
- Fiscal Year End N/A
- Average Stock Price Target $46.50
- High Stock Price Target $58.00
- Low Stock Price Target $19.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.23
- Trailing P/E Ratio -8.37
- Forward P/E Ratio -8.37
- P/E Growth -8.37
- Net Income $-643,202,000
Income Statement
Quarterly
Annual
Latest News of BBIO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
UFC Denver Fight Card Preview, Odds & Predictions: Ponzinibbio Vs. Salikhov
The co-main event at UFC Denver features a welterweight clash between Santiago Ponzinibbio and Muslim Salikhov. Both fighters aim to recover from losses, with Ponzinibbio as a favorite....
By Forbes | 2 months ago -
BridgeBio Pharma, Inc. (BBIO): Is This Healthcare Stock a Strong Buy?
A list of top healthcare stocks under $50 includes BridgeBio Pharma, Inc. Among hedge funds' radar, healthcare stocks offer steady returns due to consistent demand. The healthcare industry is growing ...
By Yahoo! Finance | 3 months ago -
BridgeBio Pharma, Inc. (BBIO) Stock Price, News, Quote & History
BridgeBio Pharma exceeds enrollment target for BBP-418 trial in LGMD2I/R9, receiving FDA Rare Pediatric Disease Designation. Interim analysis results expected in 2025, aiming for Accelerated Approval....
By Yahoo! Finance | 3 months ago
